Are Vectura Group PLC, AstraZeneca plc And Lookers PLC ‘Screaming Buys’?

Should you add these 3 stocks to your portfolio? Vectura Group PLC (LON: VEC), AstraZeneca plc (LON: AZN) and Lookers PLC (LON: LOOK)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in pharmaceutical development company Vectura (LSE: VEC) have soared by around 10% today after it announced two pieces of very positive news flow. The first is that the FDA has approved the dual combination Utibron Neohaler and standalone monotherapy Seebri Neohaler products for treatment of chronic obstructive pulmonary disease (COPD). This has triggered a milestone payment of $22.5m from Novartis to Vectura as part of the deal agreed between the two companies regarding the treatment.

Hugely positive

Additionally, Vectura has also announced a €750k milestone payment from Novartis’s subsidiary Sandoz, relating to a development milestone for VR632, which is a generic, combined therapy for asthma/COPD.

Clearly, today’s news is hugely positive for Vectura, but despite its share price rise it still seems to offer excellent value for money. Certainly, its forward price to earnings (P/E) ratio of 95 may put a number of investors off, but with its bottom line forecast to rise by 141% next year, it puts Vectura on a price to earnings growth (PEG) ratio of only 0.3. This indicates that its shares appear to be well-worth buying for the long term.

Of course, the health care space offers other excellent opportunities. AstraZeneca (LSE: AZN) has endured a number of challenges in recent years, but now appears to have the right strategy with which to return to bottom line growth over the medium term.

Prudent buys

It has focused on engaging in M&A activity, with its strong balance sheet and excellent cash flow providing a great deal of opportunity in this space. Furthermore, the assets it has purchased seem to be very prudent buys, with its focus on treatments for global illnesses such as diabetes which are set to rapidly grow in prevalence in the coming years likely to offer a clear pathway to long term growth.

With AstraZeneca trading on a P/E ratio of just 15.3, it appears to offer excellent value for money. Certainly, its investors may need to be patient because profit growth may not return in the short run but, for investors taking a longer term view, now seems to be the perfect time to buy AstraZeneca — especially since its share price now appears to be exclusive of a bid premium.

Continued growth

Meanwhile, good news was also released today by car sales company Lookers (LSE: LOOK). Trading in its most recent quarter was in-line with expectations and it achieved record monthly performance in September. Crucially, integration of the 30 dealerships acquired through the purchase of Benfield Motor Group is progressing well, with them making a major contribution to the company’s financial performance.

Looking ahead, Lookers is forecast to increase its bottom line by 7% in the current year and by a further 10% next year. Despite this upbeat growth rate, its shares trade on a PEG ratio of only 1.1 and this indicates that they could be due for continued capital growth after posting a rise of 34% year-to-date. As such, now appears to be a good moment to buy a slice of Lookers.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Despite rising 152% in a year, is Rolls-Royce’s share price still a bargain?

While Rolls-Royce’s share price has shot up recently, it still looks very undervalued against its peers, and the business looks…

Read more »

Investing Articles

Could Nvidia stock be a bargain in plain sight?

Nvidia stock has surged 252% over the past 12 months, but that doesn't mean it's expensive. In fact, it may…

Read more »

Investing Articles

Here’s why I think the Vodafone share price should be 110% higher

Reflecting on speculation, our writer believes there’s a case to be made for the Vodafone share price being more than…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Is this dividend star also the best bargain in the FTSE 100?

This FTSE 100 stock pays a whopping 8%+ yield, looks very undervalued against its peers, and is set for stellar…

Read more »

Investing Articles

2 FTSE 100 stocks. One sublime, the other ridiculous

Our writer doesn’t understand the appeal of Ocado. But looking at the grocer’s latest results makes him see the attraction…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Down 18% in a year, what’s next for the Greatland Gold (GGP) share price?

The Greatland Gold share price has disappointed over the past 12 months. Our writer asks whether the company’s latest update…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

With 30% annual returns for a decade, I’m buying this for my Stocks & Shares ISA

Oliver Rodzianko has been looking for a new investment for his Stocks and Shares ISA. Here's one he's decided is…

Read more »

Investing Articles

These were the FTSE 100’s dogs and stars in February

The FTSE 100 limped along last month, but some Footsie shares soared while others slumped. Here are February's winners and…

Read more »